ArticleAnnals of surgical oncology2025
Can Contralateral Template Dissection be Avoided in Post-chemotherapy Retroperitoneal Lymph Node Dissection for Non-seminomatous Germ Cell Tumors?
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBilateral retroperitoneal lymph node dissection (RPLND) has been the standard of care in non-seminomatous germ cell tumor (NSGCT) with residual nodes following chemotherapy. Extensive dissection leads to increased morbidity, especially sexual dysfunction. Hence, avoiding contralateral RPLND in select patients can reduce morbidity without affecting oncological outcomes. This article explores the feasibility of one such option. PATIENTS AND
methodsPatients diagnosed with testicular NSGCT with metastasis to the ipsilateral retroperitoneal (RP) lymph node template measuring ≤ 5 cm, and no involvement of the contralateral RP template (defined as low volume metastasis), who received chemotherapy and underwent bilateral RPLND, were included in the study. Clinicopathological data, perioperative complications, and oncological outcomes were collected retrospectively and analyzed.
resultsA total of 33 patients were analyzed who had undergone open bilateral RPLND with contralateral nerve-sparing template for NSGCT following chemotherapy. The median age of patients was 25.8 years, with a median follow-up of 75.6 months. A total of 14 patients reported absent ejaculation, 19 reported normal ejaculation, and 7 had decreased volume. Histology of contralateral RPLN was normal in all patients. The 5-year disease-free survival was 98%, and 5-year overall survival was 100%.
conclusionsOur data on bilateral RPLND for patients with NSGCT (meeting criteria for low-volume disease) following chemotherapy shows the absence of metastasis to the contralateral RPLN with good disease-free survival and overall survival. Hence, a future option of avoiding contralateral RPLND can be offered in select patients to reduce morbidity without compromising oncological outcomes.
Indexed as
Identifiers
40670843What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.